127 related articles for article (PubMed ID: 33392505)
1. Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma.
Baker TG; Alden J; Dubuc AM; Welsh CT; Znoyko I; Cooley LD; Farooqi MS; Schwartz S; Li YY; Cherniack AD; Lindhorst SM; Gener M; Wolff DJ; Meredith DM
Neurooncol Adv; 2020; 2(1):vdaa155. PubMed ID: 33392505
[TBL] [Abstract][Full Text] [Related]
2. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
Cantero D; Mollejo M; Sepúlveda JM; D'Haene N; Gutiérrez-Guamán MJ; Rodríguez de Lope Á; Fiaño C; Castresana JS; Lebrun L; Rey JA; Salmon I; Meléndez B; Hernández-Laín A
Neurooncol Adv; 2020; 2(1):vdz059. PubMed ID: 32642724
[TBL] [Abstract][Full Text] [Related]
3. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin.
Martinez-Diaz H; Kleinschmidt-DeMasters BK; Powell SZ; Yachnis AT
Arch Pathol Lab Med; 2003 Sep; 127(9):1187-91. PubMed ID: 12946225
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic analysis of giant cell glioblastomas.
Meyer-Puttlitz B; Hayashi Y; Waha A; Rollbrocker B; Boström J; Wiestler OD; Louis DN; Reifenberger G; von Deimling A
Am J Pathol; 1997 Sep; 151(3):853-7. PubMed ID: 9284834
[TBL] [Abstract][Full Text] [Related]
5. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
6. Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features.
Yang SR; Jayakumaran G; Benhamida J; Febres Aldana CA; Fanaroff R; Chang J; Gedvilaite E; Villafania LB; Sauter JL; Offin M; Zauderer MG; Ladanyi M
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38630790
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations.
Martinez R; Roggendorf W; Baretton G; Klein R; Toedt G; Lichter P; Schackert G; Joos S
Cancer Genet Cytogenet; 2007 May; 175(1):26-34. PubMed ID: 17498554
[TBL] [Abstract][Full Text] [Related]
8. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic alterations in glioblastomas with oligodendroglial component.
Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
11. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
[TBL] [Abstract][Full Text] [Related]
12. Glioblastomas harboring gene fusions detected by next-generation sequencing.
Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
[TBL] [Abstract][Full Text] [Related]
13. Integrated molecular characterization of IDH-mutant glioblastomas.
Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma.
Richardson TE; Kumar A; Xing C; Hatanpaa KJ; Walker JM
J Neuropathol Exp Neurol; 2020 Oct; 79(10):1031-1037. PubMed ID: 32954439
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma.
Jin MC; Wu A; Xiang M; Azad TD; Soltys SG; Li G; Pollom EL
World Neurosurg; 2019 Aug; 128():e217-e224. PubMed ID: 31009783
[TBL] [Abstract][Full Text] [Related]
17. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
19. Landscape of Genomic Alterations in
Yan Y; Takayasu T; Hines G; Dono A; Hsu SH; Zhu JJ; Riascos-Castaneda RF; Kamali A; Bhattacharjee MB; Blanco AI; Tandon N; Kim DH; Ballester LY; Esquenazi AY
JCO Precis Oncol; 2020 Nov; 4():575-584. PubMed ID: 35050747
[TBL] [Abstract][Full Text] [Related]
20. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
